Stock 6990 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:28 2024-05-24 am EDT 		5-day change 1st Jan Change
175.9 HKD +0.92% Intraday chart for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. +3.05% +70.94%
May. 24 Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO MT
May. 24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting
CI
Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares
MT
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%
MT
Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024
CI
Kelun-Biotech Shrinks Loss by 7% in 2023
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China Healthcare Stocks Rally on Hopes for Government Support
DJ
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration
CI
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect
MT
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5%
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC
CI
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3%
MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.(SEHK:6990) added to S&P Global BMI Index
CI
China Accepts Kelun-Biotech's Application for Triple-Negative Breast Cancer Treatment; Shares Fall 4%
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6990 Stock
  4. News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.